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1 
Summary 
 
Cancers arise through the acquisition of oncogenic mutations and grow through clonal 
expansion1,2. Here we reveal that most mutagenic DNA lesions are not resolved as mutations 
within a single cell-cycle. Instead, DNA lesions segregate unrepaired into daughter cells for 5 
multiple cell generations, resulting in the chromosome-scale phasing of subsequent 
mutations. We characterise this process in mutagen-induced mouse liver tumours and show 
that DNA replication across persisting lesions can produce multiple alternative alleles in 
successive cell divisions, thereby generating both multi-allelic and combinatorial genetic 
diversity. The phasing of lesions enables the accurate measurement of strand biased repair 10 
processes, the quantification of oncogenic selection, and the fine mapping of sister chromatid 
exchange events. Finally, we demonstrate that lesion segregation is a unifying property of 
exogenous mutagens, including UV light and chemotherapy agents in human cells and 
tumours, which has profound implications for the evolution and adaptation of cancer 
genomes. 15 
 
 
2 
Main text 
 
Sequencing and analysis of cancer genomes have identified a wealth of driver mutations and 
mutation signatures1,3, illustrating how environmental mutagens cause genetic damage and 20 
elevate cancer risk4,5. The diversity of mutation patterns identified from cancer genome 
sequencing is testament to the temporal and spatial heterogeneity of exogenous and 
endogenous exposures, mutational processes, and germline variation amongst patients. A 
recent study of diverse human cancers identified 49 distinct single base substitution 
signatures, with almost all tumours demonstrating evidence of at least three signatures3.  25 
 
Such intrinsic heterogeneity leads to overlapping mutation signatures that confound our 
ability to accurately disentangle the biases of DNA damage and repair, or to interpret the 
dynamics of clonal expansion. We reasoned that a more controlled and genetically uniform 
cancer model system would overcome some of these limitations and complement human 30 
cancer studies. By effectively re-running cancer evolution hundreds of times, we aimed to 
explore oncogenesis and mutation patterns at high resolution and with good statistical power.  
 
We chemically induced liver tumours in fifteen-day-old (P15) male C3H/HeOuJ inbred mice 
(Fig. 1a; subsequently C3H, n=104) using a single dose of diethylnitrosamine (DEN), thus 35 
greatly extending our previous study6. To provide a genetic comparison and a validation 
dataset in a divergent mouse strain7, we treated a cohort of CAST/EiJ mice with DEN 
(subsequently CAST, n=54).  
 
Whole genome sequencing (WGS) of 371 independently-evolved tumours from 104 C3H 40 
mice (Supplementary Table 1) revealed that each genome harboured ~60,000 somatic 
point mutations, which equates to 13 mutations per megabase (Fig. 1b) and is comparable 
to human cancers caused by exogenous mutagen exposure such as tobacco smoking and 
UV exposure8,9. Insertion-deletion mutations, larger segmental changes, and aneuploidies 
were rare (Extended Data Fig. 1a-f). The tumour genomes were dominated (76%) by 45 
T→N/A→N mutations (where N represents any alternate nucleotide, Fig. 1c), consistent with 
previous studies implicating the long-lived thymine adduct O4-ethyl-deoxythymine as one of 
the principal mutagenic lesions generated through bioactivation of DEN by cytochrome P450 
(CYP2E1)10. In addition to the predominantly T→N signature (subsequently DEN1), 
deconvolution of mutation signatures revealed a second signature prominent in a minority of 50 
tumours (DEN2) but typically present at a low level (Extended Data Fig. 1g-j). DEN2 is 
mainly composed of C→T/G→A substitutions, likely representing O6-ethyl-2-
deoxyguanosine10, which can be repaired by the enzyme MGMT11. Known driver mutations 
were identified in the EGFR/RAS/RAF pathway6,12,13 (Fig. 1d). These exhibited a strong 
propensity to be mutually exclusive: 82% of C3H tumours had only a single known driver 55 
mutation. Similar results were replicated in CAST mice (Extended Data Fig. 1i,j). 
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Fig.1 | DEN-initiated tumours have a high burden of point mutations with a distinct mutation 
signature and driver mutations in the EGFR/RAS/RAF pathway. a, Fifteen-day-old (P15) male 60 
C3H/HeOuJ mice received a single dose of diethylnitrosamine (DEN); tumours were isolated 25 weeks 
after DEN treatment (P190), histologically analysed and subjected to whole genome sequencing. b, 
DEN-induced tumours displayed a median mutation rate of 13 mutations per million base pairs (μ/Mb). 
c, Mutation spectra histogram for the aggregated mutations of 371 C3H tumours showing the 
distribution of nucleotide substitutions, stratified by flanking nucleotide sequence context (96 65 
categories). Sequence context for every fourth trinucleotide context is annotated (x-axis). d, Oncoplot 
summarising each tumour as a column with its mutation rate (black) and the presence of driver 
mutations in known driver genes (brown boxes). Tumours are ordered by the driver mutations 
identified.  
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Chromosome-scale segregation of lesions 70 
Strikingly, in each tumour genome we observed multi-megabase segments with pronounced 
Watson versus Crick strand asymmetries of mutation spectra (Fig. 2). We define Watson 
strand bias as an excess of T→N over A→N mutations, when called on the forward strand of 
the reference genome, and the opposite as Crick strand bias. The asymmetrically mutated 
segments often encompass an entire chromosome, and have a median span of 55Mb (Fig. 75 
2a-d). The scale of these segmental asymmetries is orders of magnitude greater than those 
generated by transcription coupled repair (TCR)14, APOBEC mutagenesis15,16, or produced 
by replication strand asymmetries14,17. Despite segmental strand asymmetry, mutation load 
remains approximately uniform across the genome (Fig. 2e) and asymmetric segments do 
not correspond to changes in DNA copy-number (Fig. 2f). 80 
 
Pervasive, strand-asymmetric mutagenesis can be explained as the consequence of DEN-
induced lesions remaining unrepaired prior to genome replication. The first round of 
replication after DEN exposure results in two sister chromatids with independent lesions on 
their parent strands (Fig. 2j). The daughter strand is produced using a lesion-containing 85 
template whose complement is synthesised with reduced replication fidelity over damaged 
nucleotides, resulting in nucleotide misincorporation errors complementary to lesions. These 
two sister chromatids necessarily segregate into separate daughter cells during mitosis. The 
heteroduplexes of lesions with paired mismatches are resolved into full mutations by later 
replication cycles (Fig. 2j). We subsequently refer to this phenomenon as “lesion 90 
segregation”.  
 
The haploid X chromosome always contains segments with a strong strand bias (Fig. 2g). 
On autosomal chromosomes, we also observe an unbiased state, which we interpret as the 
aggregated biases of the two allelic autosomal chromosomes with opposing strand 95 
asymmetries. More explicitly, when both copies of a chromosome have Watson bias, the 
genome shows a Watson bias (e.g. chromosome 15 in Fig. 2a-d); when one copy has 
Watson bias and the other a Crick bias the two will cancel each other out and appear 
unbiased (e.g. chromosome 19 in Fig. 2a-d). Under lesion segregation, these asymmetries 
represent the random retention of Watson or Crick biased segments over the whole genome, 100 
and are essentially the output of two independent 1:1 Bernoulli processes, analogous to two 
fair coin flips. In such a model, we expect (1) 50% of the autosomal genome and (2) 100% of 
the haploid X chromosome to show mutational asymmetry; both predictions are supported by 
the observed data (Fig. 2g,i). A small fraction of tumours (3.5%) are outliers (Fig. 2g,i), with 
absent or muted mutational asymmetry; these features are associated with atypically low 105 
variant allele frequency distributions, indicating they may be polyclonal or polyploid 
(Supplementary Table 1). The asymmetric regions show a 23-fold (median) excess of their 
preferred mutation over its reverse complement, suggesting that >95% of those lesions that 
go on to produce a mutation, segregate for at least one mitosis.  
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Fig.2 | Chromosome-scale and strand asymmetric segregation of DNA lesions. a-f, An example 110 
DEN-induced C3H tumour (identifier: 94315_N8) with the genome shown over the x-axis. a-c, 
Mutational asymmetry. Individual T→N mutations shown as points, blue (T on the Watson strand, a) 
and gold (T on the Crick strand, c), the y-axis representing the distance to the nearest neighbouring 
T→N mutation on the same strand. b, Segmentation of mutation strand asymmetry patterns. Y-axis 
position shows the degree of asymmetry (no bias: grey); mutational symmetry switches indicated as 115 
red lines. d, Segmentation profile summarised as ribbon showing only the asymmetric segments. e, 
Mutation rate in 10Mb windows, blue line shows the genome wide rate for this tumour. f, DNA copy 
number in 10Mb windows (grey) and for each asymmetry segment (black). g, Summary ribbon plots 
(as in d) for all 371 C3H tumours, ranked by chromosome X asymmetry. Purple triangle indicates 
tumour shown in panels a-f. Reference genome mis-assembly points marked (grey diamonds). h, 120 
Balance of Watson versus Crick asymmetry amongst tumours, showing deviations at driver genes. i, 
Tumours consistently show segmental mutational asymmetry across 50% of their autosomal genome. 
j, Model for DNA lesion segregation as a mechanism to generate mutational asymmetries. The 
exposure of a mutagen generates lesions (red triangles) on both strands of the DNA duplex (1). If not 
removed before or during replication (2) those lesions will segregate into two sister chromatids, one 125 
(blue) carrying only Watson strand lesions and subsequent templated errors, and the second (gold) 
only Crick strand lesions and their induced errors. Following mitosis, the daughter cells will have a 
non-overlapping complement of mutagen-induced lesions and resulting replication errors (3), which 
are resolved into full mutations in the next round of replication (4). The lesion containing strands 
segregate, becoming a progressively diminishing fraction of the lineage, yet continue as a template for 130 
replication. Only cell lineages containing cancer driver changes (* in step (1)) will expand into 
substantial clonal populations (5). 
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Resolving sister chromatid exchange 
The lesion segregation model predicts mutational asymmetries should span whole 
chromosomes, yet we commonly observe discrete switches between multi-megabase 135 
segments of Watson and Crick bias within a chromosome (Fig. 2a-d,g). Such switches likely 
represent sister chromatid exchanges (SCEs) resulting from homologous recombination (HR) 
mediated DNA repair events18 (Extended Data Fig. 3a) that are typically invisible to 
sequencing technologies because HR between sister chromatids is generally thought to be 
error-free19. 140 
 
The observed rate of sister-chromatid exchange positively correlates with the genome-wide 
load of point mutations (Extended Data Fig. 2a,b). The presence of ~27 (median) SCEs in 
each of 371 diploid tumour genomes meant we were well-powered to detect recurrent 
exchange sites and biases in genomic context (Extended Data Fig. 2c,d). After filtering out 145 
three reference genome mis-assemblies (Fig. 2g; Extended Data Fig. 2e,f), we find that 
SCEs occur throughout the genome, with modest enrichment in transcriptionally inactive, late 
replicating regions (Extended Data Fig. 3b). 
 
The fine mapping (~20kb resolution) of SCEs allowed us to test the fidelity of HR between 150 
sister chromatids. The mutation rate appears locally elevated at SCEs, but the spectrum of 
mutations matches the rest of the genome (Extended Data Fig. 3c-f). We propose that a 
model of Holliday intermediate branch migration could explain these observations (Extended 
Data Fig. 3g). 
 155 
Lesion segregation reveals oncogenic selection 
The random segregation of sister chromatids into daughter cells would result in 50% Watson 
and 50% Crick strand lesion retention on average across tumours, and the majority of the 
genome conforms to this prediction (Fig. 2h). We observe striking deviations at loci spanning 
known murine hepatocellular carcinoma driver genes (Fig. 2h). For example, the Braf T→A 160 
mutation at codon 584 is a known oncogenic driver 6 and is observed in 153/371 C3H 
tumours. Presuming that the Braf mutation was DEN induced, we would expect the mutation 
to have occurred in a chromosomal segment that retained T-lesions on the same strand as 
the driver T→A change. Indeed this is the case (94%; 144/153 tumours retain lesions on the 
expected strand, Fisher’s exact test p=3.6x10-19, rejecting the 50:50 null expectation). In 165 
contrast, tumours lacking the Braf mutation do not show a systematic bias (47% Crick bias, 
53% Watson bias, p=0.88, not rejecting the 50:50 null expectation). We applied this general 
test for oncogenic selection at sites with sufficient recurrent mutations to have statistical 
power. Our results confirmed significant oncogenic selection of previously identified driver 
mutations in Hras, Braf and Egfr (Fig. 1d; Extended Data Table 1).  170 
 
DNA repair with lesion strand resolution 
Resolving DNA lesions to specific strands in a single mutagenised cell cycle presents a 
unique opportunity to investigate strand-specific interactions with DNA damage and repair in 
vivo. In expressed genes, transcription-coupled nucleotide excision repair specifically 175 
removes DNA lesions from the mRNA template strand rather than from the non-template 
strand (Fig. 3a)20,21. To explore this, we generated total transcriptomes of liver tissue from 
 
 
7 
P15 C3H and CAST mice, corresponding to the known tissue of origin as well as the exact 
developmental timing of DEN mutagenesis. 
 180 
For each gene in each tumour, we resolved whether the lesion-containing strand was the 
mRNA template or not, and calculated mutation rates stratified by both expression level and 
lesion strand (Fig. 3b). As expected, TCR was highly specific to the template strand and 
correlated closely with gene expression. Among genes without detectable expression, there 
was no reduction or observable transcription strand-bias in the mutation rate. In contrast, 185 
mutation in the most highly expressed genes was reduced by 79.8±1.0%, if the tumour 
inherited lesions on the template strand. We also detected a small transcription-associated 
decrease of 10.7±1.4% in mutation rate for lesions on the non-template strand, relative to 
lowly-expressed genes. 
 190 
We next considered the specificity of TCR, comparing the rates of mutation for each 
trinucleotide context between template and non-template strands, stratified by expression 
level (Fig. 3c,d). The most common mutations (T→N), have an 82% (s.d. 6.8% across 
sequence contexts) lower rate on the template strand than the non-template strand for highly 
expressed genes; the non-template mutation rate is the same regardless of expression level 195 
(Fig. 3d, dark-blue lines are close to vertical), as expected20. 
 
Mutations from C and G on the template strand show a high efficiency of TCR (70% (s.d. 
7.8%) and 34% (s.d. 21%) respectively, Fig. 3d), but there is a consistent transcription-
dependent reduction of mutation rate when these lesions are on the non-template strand 200 
(lines are deflected from vertical), possibly revealing activity of non-TCR repair processes in 
accessible genic regions. Though comparatively rare, mutations from adenine on the lesion 
containing strand are increased with transcription (Fig. 3d). This unexpected observation 
could be due to the activity of error-prone translesion DNA polymerase Pol-η which targets 
transcribed regions, where it specifically mutates A:T base-pairs22. 205 
 
Prior analyses of TCR could not resolve the lesion containing strand14,20,23. Consistent with 
these previous findings, we observe reduced mutation rates broadly across the transcription 
start site (TSS) region and into active gene bodies (Fig. 3e). A notable feature of this profile 
is the relative increase in mutation rate for the core promoter located in the 200 nucleotides 210 
immediately upstream of the TSS24. Including lesion strand information in the analysis (Fig. 
3f,g) shows the relative increase in mutation rate over the core promoter to be a result of 
high rates of TCR upstream and downstream, but a relative depletion of TCR activity over 
the promoter itself, results that are replicated in CAST mice (Extended Data Fig. 4a-e). The 
ability to resolve the lesion strand newly reveals the striking and distinct contributions of 215 
bidirectional transcription from active promoters25 in shaping the observed mutation patterns.  
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Fig.3 | Identification of the lesion containing DNA strand allows processes such as 
transcription coupled repair (TCR) to be quantified with strand specificity. a, TCR of DNA 
lesions is expected to reduce the mutation rate only when lesions are on the template strand of an 
expressed gene. b, TCR of template strand lesions is dependent on transcription level (P15 liver, 220 
transcripts per million (TPM)). Confidence intervals (99%) are shown as whiskers. c, Comparison of 
mutation rates for the 64 trinucleotide contexts: each context has one point for low and one point for 
high expression. d, Data as in panel c plotted on log scale; there is a line linking low and high 
expression for the same trinucleotide context. e, Sequence composition normalised profiles of 
mutation rate around transcription start sites (TSS). f, Stratifying the data plotted in e by lesion strand 225 
reveals much greater detail, including the pronounced net influence of bidirectional transcription 
initiation on the observed mutation patterns. g, TSS region detail from panel above, f. 
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Lesion segregation generates genetic diversity 
The lesion segregation model (Fig. 2j) predicts that a segregating lesion may template 
multiple rounds of replication in successive cell cycles. In such a scenario, each replication 230 
across the lesion could incorporate different incorrectly paired nucleotides - or even the 
correctly paired nucleotide - opposite a persistent lesion. Consistent with this notion, 
hundreds of multi-allelic mutations have recently been reported from single cell sequencing 
of human cancer samples26 and a well-controlled cell lineage tracking system27. 
 235 
We investigated the extent of multi-allelic variation within each liver tumour genome by 
analysing the sequencing reads overlapping identified mutations. For example, a nucleotide 
position with multiple high-confidence reads supporting a reference T, mutation to A and also 
mutation to C would be considered multi-allelic. On average, 8% of mutated sites in DEN 
induced tumours exhibit evidence of multi-allelic variants (n=1.8 million sites in C3H 240 
tumours), though this value ranges from <1% to 25.7% between tumours (Fig. 4a). As a 
control we performed equivalent analysis on sites that had been called as mutated in a 
randomly selected proxy tumour; on average, only 0.098% (95% CI: 0.043-0.25%) show 
evidence of non-reference nucleotides.  
 245 
We further validated the multi-allelic variant calls from whole genome sequencing within 
independently performed exome sequencing of the same tumours6. The second and 
subsequent alternate alleles show the same profile of read depth-dependent validation rate 
as the called mutant allele, and clear separation from control analyses with mis-paired 
exome and genome sequence (Fig. 4b). 250 
 
The independent generation of multi-allelic variation across the genome produces 
combinatorial genetic diversity not expected under purely clonal expansion. This 
combinatorial diversity can be directly visualised in pairs of mutated sites close enough to be 
spanned by individual sequencing reads (Fig. 4c,d). These reads report allele combinations 255 
that required lesions to have been replicated over without generating a mutation in some cell 
divisions (Fig. 4d). Allele frequency distributions indicate that non-mutagenic synthesis over 
DNA lesions is common (Extended Data Fig. 5). As expected for orthogonal measures of 
the generated genetic diversity, the tumour-wide level of combinatorial diversity from 
proximal mutation pairs closely correlates with the multi-allelic rate (Fig. 4e), and highlights 260 
the consistently high variance of these measures between tumours. 
 
The explanation for this inter-tumour variance becomes evident when plotting the distribution 
of multi-allelism along each tumour genome (Fig. 4f-i). Tumours with high rates of genetic 
diversity typically have uniformly high rates of multi-allelism across their genome (Fig. 4g). 265 
They likely developed from a first generation daughter of the original DEN mutagenised cell, 
in which all DNA is a duplex of a lesion containing and non-lesion containing strand. 
Replication over lesion containing strands in subsequent generations produces multi-allelic 
variation at a uniform rate throughout the genome.  
 270 
Tumours with lower total levels of genetic diversity exhibit discrete genomic segments of high 
and low multi-allelism (Fig. 4h,i). These tumours can be explained as having developed from 
a cell a few generations subsequent to DEN treatment. Each mitosis following DEN exposure 
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is expected to dilute the lesion containing strands present in each daughter cell by 
approximately 50%, assuming random segregation. Only lesion-retaining fractions of the 275 
genome generate multi-allelic and combinatorial genetic diversity in the daughter lineages. 
As expected from the lesion segregation model with SCE, the multi-allelic patterns mirror the 
mutational asymmetry segmentation pattern. 
 
By estimating the fraction of multi-allelic chromosomal segments, we can infer the cell 280 
generation post-DEN exposure that the tumour grew from (Fig. 4j). 67% of C3H and 21% of 
CAST tumours developed from first generation daughter cells following DEN exposure, 
indicating the single large burst of mutations was instantly transformative. For the remainder, 
the observed fractions of multi-allelic segments cluster around expectations for second and 
subsequent cell generations, suggesting that the production of a specific mutant allele 285 
combination, an additional mutation, or an external trigger was required for transformation. 
Intriguingly, Egfr driven tumours appear to transform significantly later after DEN treatment, 
suggesting that driver gene identity may influence the timing of tumour inception (Fig. 4k).  
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Fig.4 | Lesion segregation generates multi-allelic and combinatorial genetic diversity. a, Percent 
of mutation sites with robust support for multi-allelic variation, one point per tumour. Grey line indicates 290 
median. Null expectation (magenta) from permutation between tumours. b, Validation rate for whole 
genome sequence (WGS) mutation calls in replication whole exome sequencing (WES). Null 
expectation from permuting tumour identity between WGS and WES. c, Sequence reads spanning 
proximal mutations, showing nucleotide calls per read. d, As c, showing combinatorial diversity 
between a pair of biallelic sites. e, Correlation between per-tumour multi-allelic rate and high 295 
combinatorial diversity mutation pairs (as in c, d), one point per tumour. f, Tree showing all possible 
progeny of a DEN mutagenised cell for the subsequent 10 generations. Blue and gold lines trace the 
simulated segregation of lesion-containing strands from a single haploid chromosome. Coloured 
nodes show hypothetical transformation events and their daughter lineages that would give rise to the 
multi-allelic patterns in tumours shown to the right. g-i, Mutation asymmetry summary ribbons for 300 
example C3H tumours that show high g, variable h, or low i rates of genetic diversity; genome on the 
x-axis. The percent of mutation sites with robust support for multi-allelic variation calculated in 10Mb 
windows (grey) and for each asymmetric segment (black). j, Histogram of the estimated cell 
generation post-DEN exposure from which C3H tumours developed based on the proportion of multi-
allelic segments. k, Enrichment of specific driver gene mutations in earlier (generation 1) and later 305 
(generation >1) developing tumours. All tumours containing the indicated driver mutation (black); the 
subset of tumours with just the indicated driver and no other driver mutation (red); multi-driver denotes 
all tumours that contain multiple identified driver genes in the EGFR/RAS/RAF pathway.   
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Lesion segregation is ubiquitous  
Lesion segregation is a major feature of DEN mutagenesis in mouse liver. This immediately 310 
raises two important questions: are other DNA damaging agents also characterised by lesion 
segregation? And does lesion segregation occur in human cells and cancers? A recent study 
exposed human induced pluripotent stem cells (iPSCs) to 79 known or suspected 
environmental mutagens and found 41 of them produced nucleotide substitutions above 
background expectations5. Although not previously noted in these data, we found that many 315 
of these exposures generated chromosome-scale lesion segregation patterns (Extended 
Data Fig. 6a-d) similar to our in vivo DEN model.  
 
For each mutagenic agent, we identified the most common nucleotide substitution type in 
each sample (e.g. C→T/G→A in simulated solar radiation exposure, Extended Data Fig. 6a) 320 
and applied runs-based tests to quantify their segmental asymmetry. The application of runs-
based tests (e.g. the rl20 metric) (Fig. 5a-f) revealed that segmental mutational asymmetry is 
a common feature of DNA damaging mutagens in human cells (Fig. 5c). We detect 
significant mutational asymmetry in every sample with good statistical power (>1,000 
informative mutations, Fig. 5e), including clinically relevant insults, such as sunlight 325 
(simulated solar radiation, SSR), tobacco smoke (BPDE) and chemotherapeutic agents 
(temozolomide). We conclude that the chromosome-scale segregation of lesions and the 
resulting strand asymmetry of mutation patterns is a general feature of all tested DNA 
damaging mutagens. 
 330 
In an analogous experiment, similar numbers of mutations were induced by perturbation of 
replication and repair pathways28. These mutator phenotypes are independent of DNA 
lesions and correspondingly significant asymmetry was neither expected nor detected (Fig. 
5d). 
 335 
A common feature of our DEN mutagenesis experiment and mutagen exposure in human 
iPSCs5 is the striking pattern of mutation asymmetry that occurs as a consequence of a 
single mutagenic insult. By contrast, most human cancers are subject to multiple damaging 
events over their history. Our lesion segregation model predicts that such tumours will 
acquire new waves of segregating lesions after each exposure, thus progressively masking 340 
and mutually confounding their mutation patterns. Therefore, even though we have shown 
that UV exposure does cause striking lesion segregation in human cells (Fig. 5a; Extended 
Data Fig. 6a), it is unlikely that the mutational asymmetry diagnostic of lesion segregation 
would be detected in skin cancers.  
 345 
Despite the low prior expectation of detecting lesion segregation patterns in human cancers, 
we used the same algorithm as for human iPSCs to search for such patterns in human 
cancer genomes29 (n=18,965 cancers from 22 primary sites). This identified multiple cancers 
that clearly show mutational asymmetry characteristic of lesion segregation (Fig. 5f,g). The 
majority of these tumours are renal, hepatic or biliary in origin, and show a high mutation rate 350 
and strand asymmetry of T→A/A→T mutations, consistent with known aristolochic acid 
exposure3 (Supplementary Table 2). We conclude that while visualised most clearly in 
tumours subjected to a single dose of a mutagen, lesion segregation has likely shaped all 
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genomes that have suffered DNA damage, which has important implications for tumour 
evolution and heterogeneity.  355 
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Fig.5 | Lesion segregation is a pervasive feature of exogenous mutagens and is evident in 
human cancers. a, The runs-based rl20 metric, calculated for the simulated solar radiation (SSR) 
clone MSMO_56.s5 (Extended Data Fig. 6a); here, 20% of informative mutations (C→T/G→A) are in 
strand asymmetric runs of 22 consecutive mutations or longer (e.g. ≥22 C→T without an intervening 
G→A). b-d, The rl20 metric and runs tests. Solid blue lines show Bonferroni adjusted p=0.05 360 
thresholds, p-values < 1x10-15 are rank-ordered. b, DEN-induced C3H tumours (this study). c, 
Mutagen exposed human cells5, colour corresponds to the mutagen key in panel g. d, Cell-lines with 
genetically perturbed genome replication and maintenance machinery28. e, All 25 mutagens identified 
as producing robust mutation spectra when human induced pluripotent stem cells are exposed5, 
grouped by type of agent. See Supplementary Table 2 for the details of abbreviated mutagen 365 
exposures. The rl20 metric (x-axis) is plotted for each replicate clone, the size of each data point is 
scaled to the number of informative mutations. f, The rl20 metric and runs tests for human cancers from 
International Cancer Genome Consortium projects. g, Mutational asymmetry in an example human 
hepatocellular carcinoma, donor DO231953, which shows a single dominant mutation signature for 
aristolochic acid exposure (43.3%).  370 
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Discussion 
 
Here we have shown that most mutation-causing DNA lesions are not resolved as mutations 
within a single cell-cycle. Instead, lesions segregate unrepaired into daughter cells for 
multiple cellular generations, resulting in chromosome-scale strand asymmetry of 375 
subsequent mutations. This suggests that lesion removal prior to replication is high fidelity, 
rarely resulting in mutations. Low fidelity replication over persistent lesions implicates the 
involvement of DNA damage tolerance mechanisms30 over genomic perfection31. Initially 
discovered in a well-powered in vivo mammalian model of oncogenesis, we also 
demonstrate that lesion segregation is ubiquitous to all tested mutagens, occurs in human 380 
cells, and is evident in human cancers. Similar patterns of asymmetry in bacterial 
mutagenesis posit that the underlying mechanisms are deeply conserved32,33.  
 
Our discovery of pervasive lesion segregation challenges long standing assumptions in the 
analysis of cancer evolution34. For example, the widely used infinite sites model35 does not 385 
allow for recurrent rounds of mutation at the same site. These findings also provide new 
opportunities for understanding cancer evolution, through the use of the mutational 
asymmetry and multi-allelic rate patterns to track events during oncogenesis and to quantify 
selection. A far-reaching implication of lesion segregation is that it may provide a window of 
opportunity for a cancer to sample the fitness of mutation combinations within the lineage, 390 
circumventing Muller’s ratchet36 and Hill-Robertson interference: low efficiency of selection 
due to the inability to separate mutations of opposing fitness effects37,38. Consequently, DNA 
damaging chemotherapeutics, particularly large or closely spaced doses generating 
persistent lesions, could inadvertently provide an opportunity for efficient selection of the 
resulting mutations. This insight may guide the development of more effective 395 
chemotherapeutic regimens.  
 
Once identified, lesion segregation is a deeply intuitive concept. Its practical applications 
provide new vistas for the exploration of genome maintenance and fundamental molecular 
biology. The discovery of pervasive lesion segregation profoundly revises our understanding 400 
of how the architecture of DNA repair and clonal proliferation can conspire to shape the 
cancer genome.  
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Methods 490 
 
Mouse colony management 
Animal experimentation was carried out in accordance with the Animals (Scientific 
Procedures) Act 1986 (United Kingdom) and with the approval of the Cancer Research UK 
Cambridge Institute Animal Welfare and Ethical Review Body (AWERB). Animals were 495 
maintained using standard husbandry: mice were group housed in Tecniplast GM500 IVC 
cages with a 12-hour light / 12-hour dark cycle and ad libitum access to water, food (LabDiet 
5058), and environmental enrichments. 
 
Chemical model of hepatocarcinogenesis 500 
15-day-old (P15) male C3H and CAST mice were treated with a single intraperitoneal (IP) 
injection of N-Nitrosodiethylamine (DEN; Sigma-Aldrich N0258; 20 mg/kg body weight) 
diluted in 0.85% saline. Liver tumour samples were collected from DEN-treated mice 25 
weeks (C3H) or 38 weeks (CAST) after treatment. All macroscopically identified tumours 
were isolated and processed in parallel for DNA extraction and histopathological 505 
examination. Non-tumour tissue from untreated P15 mice (ear, tail, and background liver) 
was sampled for control experiments.  
 
Tissue collection and processing  
Liver tumours of sufficient size (≥2 mm diameter) were bisected; one half was flash frozen in 510 
liquid nitrogen and stored at -80°C for DNA extraction, and the other half was processed for 
histology. Tissue samples for histology were fixed in 10% neutral buffered formalin for 24 h, 
transferred to 70% ethanol, machine processed (Leica ASP300 Tissue Processor; Leica, 
Wetzlar, Germany), and paraffin embedded. All formalin-fixed paraffin-embedded (FFPE) 
sections were 3 μm in thickness. 515 
 
Histochemical staining 
FFPE tissue sections were haematoxylin and eosin (H&E) stained using standard laboratory 
techniques. Histochemical staining was performed using the automated Leica ST5020; 
mounting was performed on the Leica CV5030.  520 
 
Imaging 
Tissue sections were digitised using the Aperio XT system (Leica Biosystems) at 20x 
resolution; all H&E images are available in the BioStudies archive at EMBL-EBI under 
accession S-BSST129.  525 
 
Tumour histopathology 
H&E sections of liver tumours were blinded and assessed twice by a pathologist (S.J.A); 
discordant results were reviewed by an independent hepatobiliary pathologist (S.E.D). 
Tumours were classified according to the International Harmonization of Nomenclature and 530 
Diagnostic Criteria for Lesions in Rats and Mice (INHAND) guidelines39. In addition, tumour 
grade, size, morphological subtype, nature of steatosis, and mitotic index were assessed 
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(Supplementary Table 1), as well as the presence of cystic change, haemorrhage, necrosis, 
or vascular invasion. 
 535 
Sample selection for WGS 
Tumours which met the following histological criteria were selected for whole genome 
sequencing (C3H n=371, CAST n=84): (i) diagnosis of either dysplastic nodule (DN) or 
hepatocellular carcinoma (HCC), (ii) homogenous tumour morphology, (iii) tumour cell 
percentage >70%, and (iv) adequate tissue for DNA extraction. Neoplasms with extensive 540 
necrosis, mixed tumour types, a nodule-in-nodule appearance (indicative of an HCC arising 
within a DN), or contamination by normal liver tissue were excluded. Since carcinogen-
induced tumours arising in the same liver are independent6, multiple tumours were selected 
from each mouse to minimise the number of animals used. A subset of normal (non-tumour) 
samples from untreated mice were also sequenced (C3H n=13, CAST n=7). 545 
 
Whole genome sequencing 
Genomic DNA was isolated from liver tissue and liver tumours using the AllPrep 96 
DNA/RNA Kit (Qiagen, 80311) according to the manufacturer's instructions. DNA quality was 
assessed on a 1% agarose gel and quantified using the Quant-IT dsDNA Broad Range Kit 550 
(Thermo Fisher Scientific). Genomic DNA was sheared using a Covaris LE220 focused-
ultrasonicator to a 450 bp mean insert size.  
 
WGS libraries were generated from 1 μg of 50 ng/ul high molecular weight gDNA using the 
TruSeq PCR-free Library Prep Kit (Illumina), according to the manufacturer's instructions. 555 
Library fragment size was determined using a Caliper GX Touch with a HT DNA 1k/12K/Hi 
Sensitivity LabChip and HT DNA Hi Sensitivity Reagent Kit to ensure 300-800 bp (target 
~450 bp).  
 
Libraries were quantified by real-time PCR using the Kapa library quantification kit (Kapa 560 
Biosystems) on a Roche LightCycler 480. 0.75 nM libraries were pooled in 6-plex and 
sequenced on a HiSeq X Ten (Illumina) to produce paired-end 150 bp reads. Each pool of 6 
libraries was sequenced over eight lanes (minimum of 40x coverage).  
 
Variant calling and somatic mutation filtering 565 
Sequencing reads were aligned to respective genome assemblies (C3H = C3H_HeJ_v1; 
CAST = CAST_EiJ_v1)40 with bwa-mem (v.0.7.12)41 using default parameters. Reads were 
annotated to read groups using the picard (v.1.124)42 tool AddOrReplaceReadGroups, and 
minor annotation inconsistencies corrected using the picard CleanSam and 
FixMateInformation tools. Bam files were merged as necessary, and duplicate reads were 570 
annotated using the picard tool MarkDuplicates. 
 
Single nucleotide variants were called using Strelka2 (v.2.8.4)43 implementing default 
parameters. Initial variant annotation was performed with the GATK (v.3.8.0)44 walker 
CalculateSNVMetrics45. Genotype calls with a variant allele frequency < 0.025 were 575 
removed. Although inbred strains were used, fixed genetic differences between the colonies 
and the reference genome, as well as small numbers of germline variants segregating within 
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the colonies were identified. For each strain, fixed differences identified as homozygous 
changes present in 100% of genotyped samples were filtered out. Segregating variants were 
filtered based on the excess clustering of mutations to animals with shared mothers. To 580 
generate a null expectation taking into account the family structure of the colonies, the 
parent-offspring relationships were randomly permuted 1,000 times. For each count of 
recurrent mutation (range 5 to 371 inclusive), we determined the null distribution of expected 
distinct mothers. Comparing this to the observed count of distinct mothers for each recurrent 
(n>4) mutation, those with a low probability (p<1x10-4, pnorm function from R (v.3.5.1)46) 585 
under the null were excluded from analyses. 
 
Copy number variation between tumours within strains was called using CNVkit (v.0.9.6)47. 
Non-tumour reference coverage was provided from non-tumour control WGS data (C3H 
n=11, CAST n=7) and per tumour cellularity estimates (see below) were provided.  590 
 
RNA-sequencing 
Total RNA was extracted from P15 liver tissue (n=4 biological replicates per strain) using 
QIAzol Lysis Reagent (Qiagen), according to the manufacturer’s instructions. DNase 
treatment and removal were performed using the TURBO DNA-freeTM Kit (Ambion, Life 595 
Technologies), according to the manufacturer’s instructions. RNA concentration was 
measured using a NanoDrop spectrophotometer (Thermo Fisher); RNA integrity was 
assessed on a Total RNA Nano Chip Bioanalyzer (Agilent) 
 
Total RNA (1 μg) was used to generate sequencing libraries using the TruSeq Stranded 600 
Total RNA Library Prep Kit with Ribo-Zero Gold (Illumina), according to the manufacturer’s 
instructions. Library fragment size was determined using a 2100 Bioanalyzer (Agilent). 
Libraries were quantified by qPCR (Kapa Biosystems). Pooled libraries were sequenced on a 
HiSeq4000 to produce ≥40 million paired-end 150 bp reads per library.  
 605 
RNA-seq data processing and analysis 
Transcript abundances were quantified with Kallisto (v.0.43.1)48 (using the flag --bias) and a 
transcriptome index compiled from coding and non-coding cDNA sequences defined in 
Ensembl v9149. Transcripts per million (TPM) estimates were generated for each annotated 
transcript and summed across alternate transcripts of the same gene for gene-level analysis. 610 
Transcription start sites (TSS) for each gene were annotated with Ensembl v91 and based 
upon the most abundantly expressed transcript. RNA-seq data are available at Array 
Express at EMBL-EBI under accession E-MTAB-8518. 
 
Genomic annotation data 615 
Mouse liver proximity ligation sequencing (HiC) data were downloaded from GEO 
(GSE65126)50, replicates were combined, then aligned to GRCm3851 and processed using 
the Juicebox (v.7.5) and Juicer scripts52 to obtain the HiC matrix. Eigenvectors were obtained 
for 500kb consecutive genomic windows over each chromosome from the HiC matrix using 
Juicebox and subsequently oriented (to distinguish compartment A from B) using GC content 620 
per 500kb bin. We used progressiveCactus53 to project the 500kb windows into the C3H 
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reference genome and Bedtools (v.2.28.0) to merge syntenic loci between 450 and 550 kb in 
size, removing the second instance where we observed overlaps. 
 
Genic annotation was obtained from Ensembl v9149 for the corresponding C3H and CAST 625 
reference genome assemblies (C3H_HeJ_v1, CAST_EiJ_v1). Genomic repeat elements 
were annotated using RepeatMasker (v.20170127)54 with the default parameters and 
libraries for mouse annotation. 
 
The analysable fraction of the genome 630 
Analysis and sequence composition calculations were confined to the main chromosome 
assemblies of the reference genome (chromosomes 1-19 and X). Using WGS of non-tumour 
liver, ear and tail samples (C3H n=11, CAST n=7) collected and sequenced 
contemporaneously with tumour samples, genome sequencing coverage was calculated for 
1kb windows using multicov in Bedtools (v.2.28.0)55. Windows with read coverage >2 s.d. 635 
from the autosomal mean were flagged as suspect in each tumour. Read coverage over the 
X chromosome was doubled in these calculations to account for the expected hemizygosity 
in these male mice. Any 1kb window identified as suspect in >90% of these non-tumour 
samples was flagged as “abnormal read coverage” (ARC) and masked from subsequent 
analysis. This masked 12.7% of the C3H and 11.5% of the CAST reference genomes 640 
yielding analysable haploid genome sizes of C3H = 2,333,783,789 nt and CAST = 
2,331,370,397 nt.  
 
Mutation rate calculations 
Mutation rates were calculated as 192 category vectors representing every possible single 645 
nucleotide substitution conditioned on the identity of the upstream and downstream 
nucleotides. Each rate being the observed count of a mutation category divided by the count 
of the trinucleotide context in the analysed sequence. To report a single aggregate mutation 
rate, the three rates for each trinucleotide context were summed to give a 64 category vector 
and the weighted mean of that vector reported as the mutation rate. The vector of weights 650 
being the trinucleotide sequence frequency of a reference sequence, for example the 
composition of the whole genome. In the case of whole genome analysis, the same 
trinucleotide counts are used in (1) the individual category rates calculation and (2) the 
weighted mean of the rates, cancelling out. For windowed comparisons of mutation rates, the 
weighted mean is calculated using the genome wide composition of trinucleotides rather than 655 
the local sequence composition, providing a compositionally adjusted mutation rate estimate. 
For mutation rates in TCR analysis, the same compositional adjustment was carried out but 
using the trinucleotide composition of the aggregate genic spans of genome (minus ARC 
regions) for normalisation. 
 660 
Mutation signatures 
The 96 category “folded” mutation counts for each of the 371 C3H tumours were 
deconvolved into the best fitting number (K) of component signatures using sigFit (v.2.0)56 
with 1,000 iterations and K set to integers 2 to 8 inclusive. A heuristic goodness of fit score 
based on cosine similarity favoured instances where K=2. The DEN1 and DEN2 signatures 665 
reported were obtained by running sigFit with 30,000 iterations for K=2. Analysis of CAST 
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tumours gave less distinct separation of signatures so the C3H derived DEN1 and DEN2 
were used for both strains. To fit signatures to each tumour we used sigFit provided with the 
DEN signatures and additional SPONT1 and SPONT2 signatures that were derived from 
equivalent WGS analysis of spontaneous (non-DEN induced) C3H tumours. 670 
 
Driver mutation identification  
Candidate driver mutations were identified by applying oncodriveFML (v.2.2.0 using the SIFT 
scoring scheme)57 and oncodriveCLUSTL (v.1.1.1)58 to mutations identified in C3H tumours. 
The only genes convincingly identified as significantly enriched for functionally impactful or 675 
clustered mutations were Hras, Braf, and Egfr. Kras appeared as marginally significant. 
These four genes were identified for C3H6. Protein altering mutations in those genes were 
annotated as driver mutations in C3H and CAST tumours. 
 
Mutational asymmetry segmentation and scoring 680 
For each tumour a focal subset of “informative” mutation types were defined, T→N/A→N 
mutations, in the case of DEN-induced tumours. The order of focal mutations along each 
chromosome was represented as a binary vector (e.g. 0 for T→N, 1 for A→N). Vectors 
corresponding to each chromosome of each tumour were processed with the cpt.mean 
function of the R Changepoint (v.2.2.2)59 package run with an Akaike information criterion 685 
(AIC) penalty function, maximum number of changepoints set to 12 (Q=12), and 
implementing the PELT algorithm for optimal changepoint detection. Following segmentation, 
the defined segments were scored for strand asymmetry, taking into account the sequence 
composition of the segment. For example in tumours with T→N/A→N informative mutations 
the number of Ts on the forward strand is the count of Watson sites GW and the number of 690 
T→N mutations is μW which together give the Watson strand rate RW=μW/GW. The forward 
strand count of As and mutations from A likewise give the Crick strand rate RC=μC/GC. From 
these two rates we calculate a relative difference metric, the mutational asymmetry score 
S=(RW -RC)/(RW+RC) . 
 695 
The parameter S scales from 1 all Watson (e.g. DEN T→N mutations) through 0 (50:50 
T→N:A→N) to -1 for all Crick (e.g. DEN A→N). For the categorical assignment, S ≥ 0.3 is 
Watson strand asymmetric, S ≤ -0.3 Crick strand asymmetric and in the range -0.3 < S < 0.3 
symmetric, though more stringent filtering was applied where noted. Segments containing 
<20 informative mutations were discarded from subsequent analyses.  700 
To test for oncogenic selection at sites with recurrent mutations, mutational asymmetry 
segments overlapping the focal mutation were categorised based on their asymmetry score 
S, as above. The test was implemented as a Fisher’s exact test with the 2x2 contingency 
table comprising the counts of chromosomes (two autosomes per cell) stratified by Watson 
versus Crick asymmetry and the presence of the focal mutation in the tumour. Tumours 705 
containing another known driver gene or recurrent mutation within the focal asymmetry 
segment were discarded from the analysis. We estimated the minimum recurrence of a 
mutation necessary to reliably detect oncogenic selection through simulation. Biased 
segregation of chromosomes containing drivers was modelled using the observed median 
excess of T→N over A→N lesions (23 fold), and random segregation of non-driver containing 710 
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strands (1:1 ratio). Our model predicted >33 C3H recurrences or >41 CAST recurrences 
would give 80% power to detect oncogenic selection if present. 
 
Tumour cellularity estimates 
We calculated tumour cellularity as a function of the non-reference read count in autosomal 715 
chromosomes (1-R/d)*2 where R is the reference read count at a mutated site and d is the 
total read depth at the site. For each tumour these values were binned in percentiles and the 
midpoint of the most populated (modal) percentile taken as the estimated cellularity of the 
tumour. Given the low rate of copy number variation across the DEN induced tumours, no 
correction was made for copy-number distortion. Skew in the variant allele frequency 720 
(VAF=(1-R/d)) distribution was calculated using Pearson’s median skewness coefficient 
implemented in R as (3(mean-median))/sd of the VAF distribution. 
 
Identifying and filtering reference genome mis-assemblies  
Since lesion segregation, mutation asymmetry patterns allow the long-range phasing of 725 
chromosome strands, they can detect discrepancies in sequence order and orientation 
between the sequenced genomes and the reference. We identified autosomal asymmetry 
segments that immediately transitioned from Watson bias (S > 0.3) to Crick (S < -0.3) or vice 
versa without occupying the intermediate unbiased state (-0.3 > S < 0.3); such “discordant 
segments” are unexpected. Allowing for ±100kb uncertainty in the position of each exchange 730 
site we produced the discordant segment coverage metric. At sites with discordant segment 
coverage >1 we calculated percentage consensus for mis-assembly M=ds/(ds+cs) where ds 
is the number of discordant segments over the exchange site and cs the number of 
concordant: where either Watson or Crick mutational asymmetry extends at least 1x106 
nucleotides on both sides of the exchange site. The approximate genomic coordinates for a 735 
C3H strain specific inversion on chromosome 6 were previously reported60. 
 
 
Sister chromatid exchange site analysis 
Identified SCE sites were aggregated across tumours from each strain. Exchange sites 740 
within 1x106 nt of known and proposed reference genome mis-assembly sites were excluded 
from analysis. The mid-point between the flanking informative mutations was taken as the 
reference genome position of the exchange event, and the distance between those flanking 
mutations as the positional uncertainty of the estimate. To generate null expectations for 
mutation rate measures, the coordinate of an exchange was projected into the genome of a 745 
proxy tumour and the mutation rates and patterns measured from that proxy tumour 
(repeated 100 times). The permutation of tumour identifiers for the selection of proxy tumours 
was a shuffle without replacement that preserved the total number of exchange sites 
measured in each tumour. 
 750 
The comparison of mutation spectra between windows was calculated as the cosine distance 
between the 96 category trinucleotide context mutation spectra for the whole genome and 
that calculated for the aggregated 5kb window. The 96 categories were equally weighted for 
this comparison. 
 755 
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Exchange site enrichment analysis used Bedtools55 shuffle to permute the genomic positions 
of exchange sites into the analysable fraction of the genome (defined above). Observed 
rates of annotation overlap were compared to the distribution of values from 1,000 permuted 
exchange sites. For genic overlaps we used Ensembl v9149 coordinates for genic spans; 
gene expression status was based on the summed expression over all annotated transcripts 760 
for the gene from P15 liver from the matched mouse strain. Expression thresholds were 
defined as >50th centile for active and <50th centile for inactive genes.  
 
A higher count of informative mutations provides greater power to identify shorter mutational 
asymmetry segments. To fairly test for correlation between nucleotide substitution rate and 765 
SCE rate we randomly down-sampled informative mutations to 10,000 per tumour genome 
and recomputed the mutational asymmetry segmentation patterns from the sampled data. 
Tumours with <10,000 informative mutations were excluded. We then correlated the total 
(not down sampled) nucleotide substitution load to the count of SCE events inferred from the 
down-sampled data. 770 
 
Transcription coupled repair calculations  
For each protein coding gene, the maximally expressed transcript isoform was identified from 
P15 liver in the matched strain (TPM expression), subsequently the primary transcripts. In 
the case of ties, transcript selection was arbitrary. Genes were partitioned into five categories 775 
based on the expression of the primary transcript: expression level 0 (<0.0001 TPM) and four 
quartiles of detected expression. 
 
Using the segmental asymmetry patterns of each tumour and the annotated coordinates 
(Ensembl v91) of the selected transcripts, we identified transcripts completely contained in a 780 
single Watson or Crick asymmetric segment and located at least 200kb from the segment 
boundary at both ends. We also applied strict asymmetry criteria of mutational asymmetry 
scores S > 0.8 for Watson and S < -0.8 for Crick asymmetry segments, though analysis with 
the standard asymmetry thresholds and no segment boundary margin give similar results 
and identical conclusions. For each transcript in each tumour we then used both the 785 
transcriptional orientation of the gene and the mutational asymmetry of the segment 
containing it to resolve the segregated lesions to either the template (anti-sense) or non-
template (sense) strand of the gene. Transcripts contained in mutationally symmetric regions 
or not meeting the strict filtering criteria were excluded from analysis. 
 790 
We then analysed mutation rates stratifying by gene expression level and the template/non-
template strand of the lesions but aggregating between tumours within the same strain. The 
transcription start site coordinates used correspond to the annotated 5’ end of the primary 
transcripts. 
 795 
Multi-allelic variation 
Aligned reads spanning genomic positions of somatic mutations were re-genotyped using 
Samtools mpileup (v.1.9)61. Genotypes supported by ≥2 reads with a nucleotide quality score 
of ≥20 were reported, considering sites with two alleles as biallelic, those with three or four 
alleles as multi-allelic. The fraction of called mutations exhibiting multi-allelic variation was 800 
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calculated for the analysable fraction of the genome, across 10Mb consecutive windows and 
also for each of the mutational asymmetry segments calculated for each tumour. 
 
A null expectation for the multi-allelic rate estimate was generated per C3H tumour; genomic 
positions identified as mutated across the other 370 tumours were down-sampled to match 805 
the mutation count in the focal tumour. Any of these proxy mutation sites with a non-
reference genotype supported by ≥2 reads and nucleotide quality score ≥20 at the focal site 
were referred to as “multi-allelic” for the purposes of defining a background expectation for 
the calling of multi-allelic variation. For each tumour, this was repeated 100 times and the 
mean reported. 810 
 
We used whole exome sequencing (WES) of fifteen C3H tumours from prior work6 that have 
subsequently been used to generate WGS data in this study as a basis for validating multi-
allelic calls. Multi-allelic variant positions derived from WGS were genotyped in WES using 
Samtools mpileup, as described above. Only sites with ≥30x WES coverage were considered 815 
and alleles were found to be concordant if a WGS genotype was supported by ≥1 read in the 
WES data. To provide a null expectation, the analysis was repeated using WES data from a 
different tumour and validation rates reported for all versus all combinations of mismatched 
WGS-WES pairs (152-15=210).  
 820 
To quantify combinatorial genetic diversity for each tumour, pairs of mutations located 
between 3-150nt apart were phased using sequencing reads that traversed both mutation 
sites. Distinct allelic combinations were counted after extraction with Samtools mpileup using 
only reads with nucleotide quality score ≥20 over both mutation sites. 
 825 
Estimating the cell generation of transformation 
Knowing the faction of lesion segregation segments that generated multi-allelic variation 
across a tumour genome allows the inference of the generation time post-mutagenesis of the 
cell from which the tumour developed, because each successive cell generation is expected 
to retain only 50% of the lesion containing segments. We estimate this fraction as follows. 830 
Let p denote the fraction of multi-allelic segments and let q be its complement, i.e. the 
fraction of non-multi-allelic segments, for each tumour genome. Segment boundaries being 
SCE sites or chromosome boundaries. In order to determine p, we re-purpose the quadratic 
Hardy-Weinberg equation: p+q=p2+2pq+q2 =1, which holds since the two possible fractions 
need to sum to unity. Given an asymmetric segment of interest in the diploid genome, there 835 
are 3 distinct scenarios: (i) both chromosomes are multi-allelic (p2), (ii) One of the 
chromosomes is multi-allelic and the other is not (pq+qp) and (iii) both chromosomes are 
non-multi-allelic (q2). The first two scenarios are not distinguishable from the data as both 
appear multi-allelic (m). However, in the third scenario, for a segment to be non-multi-allelic 
(biallelic, b), both chromosomal copies have to be non-multi-allelic. As described below, q2 840 
can be estimated directly from the data and is subsequently used to estimate p=1-sqrt(q2) 
and hence the cell generation number of transformation post-mutagenesis.  
 
The estimation of q2 requires computing the ratio q2=b/(b+m). We can directly observe the 
counts of b as non-multi-allelic segments. The number of autosomal chromosome pairs 845 
(n=19) and count of sister chromatid exchange events (x) give the total number of segments 
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in the genome b+m=n+x. Exchange events are not expected to align between allelic 
chromosomes which will result in the partial overlap of segments between allelic copies. 
Although this increases the number of observed segments (b and m) relative to actual 
segments, assuming the independent behaviour of allelic chromosomes and that segment 850 
length is independent of multi-allelic state, this partial overlap does not systematically distort 
the quantification of b or the estimation of q2.  
 
To call a non-multi-allelic segment (b) we require less than 0.04% multi-allelic sites. The 
threshold based on the tri-modal frequency distribution of multi-allelic rates per-segment, 855 
aggregated over all 371 C3H tumours. The 0.04% threshold separates the lower distribution 
of multi-allelic rates from the mid and higher distributions. 
 
To test for the enrichment of specific driver gene mutations in early generation versus late 
generation transformation post-DEN treatment, we applied Fisher’s exact test (fisher.test 860 
function in R) to compare the generation 1 ratio of tumours with, versus those without a focal 
mutation, to the same ratio for tumours inferred to have transformed in a later generation. We 
additionally report the same odds ratios, but requiring that the “with focal mutation” tumours 
had a driver mutation in only one of the driver genes: Hras, Braf, or Egfr. 
 865 
Cell-line and human cancer mutation analysis 
Somatic mutation calls were obtained from DNA maintenance and repair pathway perturbed 
human cells28. Of the 128,054 reported single nucleotide variants, 6,587 unique mutations 
(genomic site and specific change) were shared between two or more sister clones, so likely 
represent mutations present but not detected in the parental clone. All occurrences of the 870 
shared mutations were filtered out leaving 106,688 mutations for analysis, although the 
inclusion of these filtered mutations does not alter any conclusions drawn. Somatic mutation 
calls from mutagen exposed cells5 were obtained, no additional filtering was applied to these 
sub-clone mutations.  
 875 
Somatic mutation calls from the International Cancer Genome Consortium (ICGC)62 were 
obtained as simple_somatic_mutation.open.* files from release 28 of the consortium, one file 
for each project. These somatic mutations have been called from a mixture of whole genome 
and whole exome sequencing. Of the 18,965 patients represented (and not embargoed in 
the release 28 dataset), 116 were excluded from analysis; these represent a distinct whole 880 
exome sequenced subset of the LICA-CN project that appear to show a processing artefact 
in the distribution of specific mutation subsets. ICGC mutations were filtered to remove 
insertion and deletion mutations and also filtered for redundancy so that each mutation was 
only reported once for each patient. Mutation signatures deconvolution was performed using 
the R MutationPatterns (v.1.4.2)63 package and COSMIC signature 22 was interpreted as 885 
aristolochic acid3. 
 
The rl20 metric and runs tests 
Amongst only the informative mutations (e.g. T→N/A→N in DEN) three consecutive T→N 
without an intervening A→N is a run of three. The R function rle was used to encode the run-890 
lengths for binary vectors of informative mutations along the genome of a focal tumour. 
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Ranking them from the longest to the shortest run, we find the set of longest runs that 
encompass 20% of all informative mutations in the tumour. The run-length of the shortest of 
those is reported as the rl20 metric. The threshold percent of mutations was defined as having 
to be less than 50%, as on average only 50% of the autosomal genomes are expected to 895 
show mutational asymmetry patterns. On testing with randomised data, the value of 20% 
gave a stable null expectation (maximum observed value of a run of five) and still 
encompassed a large fraction of the informative mutations. All rl20 results reported were 
implemented so that runs were broken when crossing chromosome boundaries. 
 900 
The Wald-Wolfowitz runs test was performed using the runs.test function of the R randtests 
(v.1.0)64 library. It was applied to binary vectors of informative changes as described above, 
with threshold=0.5.  
 
The Wald-Wolfowitz runs test significance is inflated by coordinated dinucleotide changes, 905 
such as those produced by UV light exposure and also other local mutational asymmetries 
such as replication asymmetry14 and kataegis events15,65. The rl20 metric appears robust to 
most such distortions but we find it efficiently detects kataegis events that are in an otherwise 
mutationally quiet background, as is often the case for breast cancer. For this reason we also 
indicate the total genomic span of mutations in the rl20 subset of mutation runs: kataegis 910 
events typically span a tiny (<5%) fraction of the whole genome. 
 
Computational analysis environment 
Primary data processing was performed in shell-scripted environments calling the software 
indicated. Except where otherwise noted, analysis processing post-variant calling was 915 
performed in a Conda environment and choreographed with Snakemake running in an LSF 
batch control system (Supplementary Table3). The analysis pipeline including Conda and 
Snakemake configuration files can be obtained from the repository 
https://git.ecdf.ed.ac.uk/taylor-lab/lce-ls.  
 920 
Data availability  
The WGS BAM files are available from the European Nucleotide Archive (ENA) under 
accession: PRJEB15138. RNA-seq files are available from Array Express E-MTAB-8518. 
Digitised histology images are available from Biostudies under accession S-BSST129.  
 925 
Key resources 
The key reagents and resources required to replicate our study are listed in Supplementary 
Table 3. For externally sourced data, where applicable, URLs that we used can be found in 
the Git repository https://git.ecdf.ed.ac.uk/taylor-lab/lce-ls.   
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Extended data 
 
Extended Data Fig.1 | Summary mutation metrics for both C3H and CAST tumours. a, Single 
nucleotide substitution rates per C3H tumour, rank ordered over x-axis (grey points, median blue line). 1050 
Insertion/deletion (indel, <11 nt) rates show as black. b, Y-axis from a, expanded to show distribution 
of indel rates with preserved tumour order. c, Number of C3H copy number variant (CNV) segments 
and their total span as a percent of the haploid genome. Blue shading shows intensity of overlapping 
points as a percent of all tumours in the plot. d-f, Corresponding plots for CAST derived tumours, f, 
two extreme x-axis outliers relocated (red) and x-axis value shown. g-h, Mutation spectra deconvolved 1055 
from the aggregate spectra of 371 C3H tumours, subsequently referred to as the DEN1 and DEN2 
signatures. i, Oncoplot summarising mutation load, mutation spectra, and driver gene mutation 
complement of C3H tumours. j, Oncoplot of CAST derived tumours as i.  
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Extended Data Fig.2 | The frequency of sister chromatid exchanges correlates with mutation 1060 
rate, and localising reference genome assembly errors. a, The relationship between single 
nucleotide substitution mutation load and detected sister chromatid exchange (SCE) events in C3H 
tumours. Counts of SCE (y-axis) are based on down-sampling to 10,000 informative mutations per 
tumour to ensure equal power to detect SCE in each tumour. Tumours with <50% cellularity (pink) 
have high mutation load and form a sub-group with few detected sister chromatid exchange events; 1065 
these are suspected to be polyclonal tumours and were excluded from the Pearson’s correlation 
reported. b, As for a but showing CAST derived tumours. c, Evaluation of the relationship between 
mutation load and ability to detect sister chromatid exchange events. Mutations from C3H tumour 
94315_N8 (shown in Fig. 2) randomly down-sampled and segmentation analysis applied. Y-axis 
shows the percentage of sister chromatid exchange events detected (100 replicates, 95% C.I. pink). 1070 
X-axis is on a log-scale: 95% of C3H and >95% of CAST tumours have mutation counts to the right of 
the blue vertical line. Down-sampling other tumours gave comparable results. d, The same down-
sampling data as shown in panel c but the y-axis shows the percent of mutations with the correct 
(same as full data) mutational asymmetry assignment. e, Candidate C3H reference genome assembly 
errors. Genome coordinates shown on the x-axis. Immediate switches between Watson and Crick 1075 
asymmetry are not expected on autosomes unless both copies of the chromosome have a SCE event 
at equivalent sites. However, inversions and translocations between the sequenced genomes and the 
reference assembly are expected to produce immediate asymmetry switches. The discordant segment 
coverage (DSC) count (black y-axis) shows the number of informative tumours (those with either 
Watson or Crick strand asymmetry at the corresponding genome position) that suggest a tumour 1080 
genome to reference genome discrepancy. Consensus support (brown y-axis) plotted as triangles 
shows the percentage of informative tumours that support a genomic discrepancy at the indicated 
position (only shown for values >50% support). The two sites on chromosome 6 in C3H correspond to 
a previously identified C3H strain specific inversion that is known to be incorrectly oriented in the C3H 
reference assembly60. f, As for e, but showing CAST tumours. The candidate mis-assembly on 1085 
chromosome 14 in both strains at an approximately orthologous position suggesting a rearrangement 
shared between strains or a missassembly in the BL6 GRCm38 reference assembly against which 
other mouse reference genome assemblies have been scaffolded.   
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Extended Data Fig.3 | Locally elevated mutation load is driven by sister-chromatid exchange.  
a, Double strand breaks (DSBs) and other DNA damage can trigger homologous recombination (HR) 1090 
mediated DNA repair between sister chromatids. The repair intermediate resolves into separate 
chromatids through cleavage and ligation; grey triangles denote cleavage sites for one of the possible 
resolutions that would result in a large-scale sister-chromatid exchange event. Although illustrated for 
double-ended DNA breaks, single ended breaks from collapsed replication forks can be repaired 
through HR and could similarly lead to the formation of repair intermediate structures that can be 1095 
resolved as SCEs. b, Enrichment analysis of sister chromatid exchanges sites (red) compared with 
null expectations from randomly permuting locations into the analysable fraction of the genome (grey 
distributions), the black boxes denote 95% of 1,000 permutations. Sister chromatid exchange events 
are enriched in later replicating and transcriptionally less active genomic regions (Hi-C defined 
compartment B), and correspondingly depleted from early replicating active regions. c, Aggregating 1100 
across n=9,645 sister chromatid exchange sites, the observed mutation rate approximately doubles at 
the inferred site of exchange (x=0). Aggregate mutation rates (brown) were calculated in consecutive 
5kb windows. Compositionally matched null expectation was generated by permuting each exchange 
site into 100 proxy tumours and calculating median (black) and 95% confidence intervals (grey) while 
preserving the total number of projected sites per proxy tumour. d, The elevated mutation count is not 1105 
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the result of a high mutation density in a subset of exchange sites, rather it is a subtle increase in 
mutations across most exchange sites. Heatmap showing mutation counts calculated in consecutive 
5kb windows across each exchange site. Rows represent each exchange site, rank-ordered by total 
mutation count across each 400kb interval. e, The distribution of positional uncertainty in exchange 
site location approximately mirrors the decay profile of elevated mutation frequency. f, Divergence of 1110 
mutation rate spectra is shown as cosine distance between the analysed window and the genome 
wide mutation rate spectrum aggregated over all C3H tumours. Despite the elevated mutation 
frequency, there is no detected distortion of the mutation spectrum. g, A model based on HR repair 
intermediate, branch migration that produces heteroduplex segments of (i) mismatch:mismatch 
(circles) and (ii) lesion:lesion (red triangles) strands. Subsequent strand segregation would increase 1115 
the mutational diversity of a descendant cell population but not the mutation count per cell (key as per 
Fig. 2).  
 
 
36 
Extended Data Table 1 | A lesion segregation based test for oncogenic selection. 
 
Strain Gene Mutation Mutation count Odds ratio P-value Known driver 
C3H Braf 6:37548568_A/T 151 2.13 5.77x10-6 Yes 
C3H Hras 7:145859242_T/C 81 2.67 6.88x10-6 Yes 
C3H Hras 7:145859242_T/A 65 1.02 1 Yes 
C3H Intronic Fmnl1 11:105081902_A/C 44 1.03 1 No 
C3H Intergenic 9:73125689_G/C 42 1.13 1 No 
C3H Egfr 11:14185624_T/A 34 3.87 1.23x10-4 Yes 
CAST Braf 6:37451282_A/T 42 1.41 0.338 Yes 
Recurrently mutated sites in both C3H and CAST with sufficient estimated power to detect oncogenic 1120 
selection through biased strand retention analysis (required >33 C3H recurrences or >41 CAST 
recurrences). Odds ratio values >1 indicate the predicted correlation of driver mutation and 
Watson/Crick strand retention in tumours with the candidate driver mutation, but not for those without 
the mutation. The Fisher’s exact test P-value is shown after Bonferroni correction. Known driver 
indicates the mutation or its orthologous change has previously been implicated as a driver of 1125 
hepatocellular carcinoma6. The CAST 6:37451282_A/T mutation is orthologous to the C3H 
6:37548568_A/T mutation.  
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Extended Data Fig.4 | Replication of transcription coupled repair with lesion strand resolution 
in Mus musculus castaneus. a, Transcription coupled repair of template strand lesions is dependent 
on transcription level (P15 liver, transcripts per million, TPM). Confidence intervals (99%) are shown 1130 
as whiskers, where broad enough to be visible. b, Comparison of mutation rates for the 64 
trinucleotide contexts: each context has one point for low and one point for high expression. c, Data as 
in panel b plotted on log scale; there is a line linking low and high expression for the same 
trinucleotide context. d, Sequence composition normalised profiles of mutation rate around 
transcription start sites (TSS). e, Stratifying the data plotted in d by lesion strand reveals much greater 1135 
detail on the observed mutation patterns, including the pronounced influence of bidirectional 
transcription initiation.  
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Extended Data Fig.5 | Variant allele frequency distributions demonstrate high rates of non-
mutagenic replication over segregating lesions. a-f, Variant allele frequency (VAF) distributions 1140 
shown as probability density functions (total area under curve=1) for example tumours, calculated 
taking into account observed multi-allelic variation. The VAF for identified driver mutations is indicated 
(brown triangle). Tumour identifiers are shown top right along with the percent of genomic segments 
(based on mutation asymmetry segmentation) that are multi-allelic. Skew shows Pearson’s median 
skewness coefficient for the VAF distributions. Panels a-c show tumours with no multi-allelic segments 1145 
and exhibit a symmetric VAF distribution showing minimal sub-clonal structure; d-f tumours with all 
segments multi-allelic, illustrating the sub-clonal structure generated by segregating lesions. g, 
Tumours with a high proportion of multi-allelic segments have a left-skewed VAF distribution indicating 
frequent non-mutagenic replication over segregating lesions. Percent of genome segments that are 
multi-allelic (x-axis) plotted against VAF distribution skew for 371 C3H tumours. Tumours with low 1150 
estimated cellularity indicated in pink and excluded from correlation analysis. h, As for g but showing 
84 CAST tumours. i, Mutation asymmetry summary ribbon for example C3H tumour 90797_N2; 
genome on the x-axis. The percent of mutation sites with robust support for multi-allelic variation (y-
axis) calculated in 10Mb windows (grey) and for each asymmetric segment (black). Thresholds for 
high (black), intermediate (grey) and zero (red) rates of multi-allelic sites shown on the right axis. j, 1155 
VAF density plots for the example tumour 90797_N2 (shown in i) mutations in asymmetry segments 
stratified by the multi-allelic rate thresholds defined in panel i. As with whole tumour based analysis (a-
h), high multi-allelic rates correspond to a leftward skew of the VAF (black, grey) whereas segments 
without multi-allelic variation (red) show a minimally skewed distribution. 
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Extended Data Fig.6 | Examples of mutation patterns generated by lesion segregation from a 1160 
diverse range of clinically relevant mutagens. a, Genome wide mutation asymmetry plot (as per 
Fig. 2a-c) for simulated solar radiation (SSR) exposed human iPSCs5 illustrating lesion segregation 
for ultraviolet damage. Immediately adjacent mutations (inter-mutation distance 100) indicate CC->TT 
dinucleotide changes. Despite a low total mutation load (1,308 nucleotide substitutions, 842 
informative T→A changes), the mutational asymmetry of lesion segregation is evident for the 1165 
aristolochic acid exposed clone5 b, and the polycyclic aromatic hydrocarbon DBADE, c that is found in 
tobacco smoke. d, Summary mutation asymmetry ribbons (as per Fig. 2d) for all mutagen exposed 
clones with rl20 >5, which illustrates the independence of asymmetry pattern between replicate clones, 
almost universal asymmetry on chromosome X, and approximately 50% of the autosomal genome 
with asymmetry over autosomal chromosomes. The dominant mutation type is indicated for each 1170 
mutagen. In those clones with low mutation rates, some sister exchange sites are likely to have been 
missed leading to reduced asymmetry signal (e.g. on the X chromosome). Segments with <20 
informative mutations are shown in white.  
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Supplementary Table 1 | Table of tumours sequenced containing key parameters & mutation 
spectra signature matrices (Excel file). 1175 
 
Supplementary Table 2 | Table of exogenous mutagen and ICGC scan results (Excel file).  
 
Supplementary Table 3 | Table of key resources and software (Excel file). 
